CANCHEN TECH
璨辰科技
CANCHEN TECH (CANCHEN TECH Shenzhen Co., Ltd.) was established in August 2025, headquartered in Shenzhen, focusing on system-level virtual organ spatiotemporal dynamic evolution models.
Position in SVTR
Snapshot 2026-11-04- Startup SignalsRankedof 2,319↓62
- Life SciencesRankedof 244↓6
- AgentsRankedof 341↓6
About
CANCHEN TECH (CANCHEN TECH Shenzhen Co., Ltd.) was established in August 2025, headquartered in Shenzhen, focusing on system-level virtual organ spatiotemporal dynamic evolution models. The technology is divided into three layers: the bottom layer is a multi-omics life foundation model, the middle layer is digital twins of core organs such as the brain, gut, and liver, and the top layer is multi-organ collaboration and full-life-cycle simulation. The core team was the first to complete a full-cycle 3D dynamic modeling of a mammalian embryo and published it in the Cell main journal. It has already been applied in collaborations with BGI Genomics Sanya Life Science Research Institute, tertiary hospitals, and national intelligent computing centers. It belongs to the AI4S computational biology/AI plus new drug evaluation direction; in July 2026, the CDE Pioneer Program (NAMs) first included AI virtual organ digital twins in the non-clinical regulatory evaluation evidence system, which is a policy advantage.
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Funding history
- 2026-08-05Angel数千万元人民币
Investors · Oriental Fortune Capital, Green Pine Capital Partners, Zero One Ventures, 水木清华校友基金, 启迪之星创投, 启繁资本, Nanshan Strategic Emerging Industry FundSource · finance.sina.com.cn ↗
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- CANCHEN TECH
System-level spatiotemporal dynamic evolution models of virtual organs: a full-scale AI dynamic simulation platform spanning molecules, cells…
Angel · 2026-08
—
United States
BusinessLatest roundTotal raisedDate- Prenuvo
Offers what it claims is a comprehensive, radiation-free MRI scan that screens for more than 500 conditions…
Series B · $120M · 2025-02
$120M - Unlearn
Creates digital twins of clinical trial participants to improve trial efficiency
Series C · $50M · 2024-02
$50M - Portal Biotechnologies
Silicon micropore mechanical-poration intracellular delivery hardware (Gateway, Millibooster, Galaxy-i, etc.) and consumables for pharma companies…
$5M
$5M
China
BusinessLatest roundTotal raisedDate- ATLATL Innovation Center
R&D infrastructure and incubation for early-stage biopharma: shared labs, resident scientists and project management, GMP process optimization…
— - Insilico Medicine
AI drug discovery company that uses generative models for target discovery and molecular design…
Series D+ · $210M · 2025-03
$210M - 智源深澜
Developer of a generative AI platform for biomolecules
Angel · $22M · 2025-11
$22M
Europe
BusinessLatest roundTotal raisedDate- Sightera Biosciences
AI-native drug discovery: patient-derived disease models and generative AI to design small-molecule cancer/fibrosis therapies
Pre-Seed · $3M · 2026-07
$3M - Isomorphic Labs
AI-driven drug design platform (IsoDDE engine): uses AlphaFold-based technology to predict protein structures and design new drug molecules; builds it…
Series B · $2.7B · 2026-05
$2.7B - Basecamp Research
Trains the EDEN foundation model on proprietary biodiversity genomic data and uses AI to design proteins and in vivo cell therapies
Series C · $200M · 2026-09
$200M
Other / unspecified
BusinessLatest roundTotal raisedDate- 深度细胞
Combines AI with multiscale molecular physics to build a "virtual cell world model" for disease mechanism discovery and drug design
Seed · $14M · 2026-08
$14M - Scopia Surgical
AI surgical navigation software combining real-time spatial intelligence and patient-specific digital twins for robot-assisted and minimally invasive …
Pre-Seed · $3M · 2026-09
$3M - Healthleap
Language models read full hospital EHR records to screen inpatients for missed malnutrition, delirium and other risks for clinical review
Series A · $38M · 2026-10
$38M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Dimension Capital
10 Life Sciences deals in the last 24 months · 4 at a nearby stage · 1 in South China
Request intro →OrbiMed Advisors
9 Life Sciences deals in the last 24 months · 3 at a nearby stage · 4 in South China
Request intro →Qiming Venture Partners
9 Life Sciences deals in the last 24 months · 3 at a nearby stage · 7 in South China
Request intro →Lilly Asia Ventures
8 Life Sciences deals in the last 24 months · 2 at a nearby stage · 7 in South China
Request intro →HongShan
7 Life Sciences deals in the last 24 months · 5 at a nearby stage · 6 in South China
Request intro →Matrix Partners China
6 Life Sciences deals in the last 24 months · 4 at a nearby stage · 4 in South China
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.